We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
坤泰胶囊联合米非司酮治疗围绝经期功能失调性子宫出血的疗效 及对 bFGF、VEGF 水平的影响.
- Authors
杨尚芝; 金 红; 李 娟; 牛玉伟
- Abstract
Objective: To analyze the therapeutic effects of Kuntai capsule combined with mifepristone on perimenopausal dysfunctional uterine bleeding (DUB) and its influence on the levels of basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF). Methods: 88 patients with perimenopausal DUB who were treated in the gynaecological clinic of Hefei First People's Hospital from October 2021 to October 2022 were selected as the study subjects. They were divided into a study group and a control group by random data table method. 44 patients were included into each group. The patients in the two groups were treated with routine symptomatic treatment after entering the group. The patients in the control group were given oral mifepristone capsules, with the dosage of 10 mg each time, once a day. On the basis of the treatment in the control group, the patients in the study group were treated with Kuntai capsule orally, with the dosage of 2 g, three times a day. The patients in the two groups were treated with continuously for 3 months. The therapeutic indexes as well as the endometrial thickness, the serum levels of follicle-stimulating hormone (FSH), luteinizing hormone (LH), prolactin (PRL), estradiol (E2), bFGF and VEGF before and after treatment for 3 months between the patients in the two groups were compared. The adverse events during treatment between the patients in the two groups were compared. Results: The distribution of efficacy grade in the study group was better than that in the control group, and the effective rate was higher than that in the control group (P<0.05). There was no statistically significant difference in the endometrial thickness and serum levels of sex hormone, bFGF and VEGF between the two groups before treatment (P>0.05). At the end of 3 months of treatment, the endometrial thickness and the serum levels of FSH, LH, PRL and E2 in the two groups were lower than those before treatment, and the serum levels of bFGF and VEGF were higher than those before treatment (P<0.05). The endometrial thickness and the serum levels of FSH, LH, PRL and E2 at the end of 3 months of treatment of the patients in the study group were lower than those in the control group, and the levels of bFGF and VEGF in serum were higher than those in the control group (P<0.05). The adverse reactions in both groups were mild and could be tolerated by patients without treatment. There was no patient who interrupted treatment due to adverse reactions. There was no significant difference between the two groups in the incidence of various adverse events and the total incidence of adverse events (P>0.05). Conclusion: In the treatment of perimenopausal DUB, the traditional Chinese and western medicine treatment scheme of Kuntai capsule combined with mifepristone is superior to that of mifepristone alone in clinical efficacy, which can improve the serum hormone levels, inhibit endometrial hyperplasia and increase the expression levels of angiogenic factors such as bFGF, VEGF more significantly.
- Subjects
FIBROBLAST growth factor 2; VASCULAR endothelial growth factors; CHINESE medicine; FOLLICLE-stimulating hormone; LUTEINIZING hormone; METRORRHAGIA; ENDOMETRIAL hyperplasia
- Publication
Progress in Modern Biomedicine, 2023, Vol 23, Issue 17, p3340
- ISSN
1673-6273
- Publication type
Article
- DOI
10.13241/j.cnki.pmb.2023.17.027